Share Name Share Symbol Market Type Share ISIN Share Description
Hemogenyx LSE:HEMO London Ordinary Share GB00BYX3WZ24 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  +0.40p +15.38% 3.00p 3,448,238 15:49:40
Bid Price Offer Price High Price Low Price Open Price
2.80p 3.20p 3.50p 2.60p 2.60p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology -1.75 -0.74 10.7

Hemogenyx (HEMO) Latest News

More Hemogenyx News
Hemogenyx Takeover Rumours

Hemogenyx (HEMO) Share Charts

1 Year Hemogenyx Chart

1 Year Hemogenyx Chart

1 Month Hemogenyx Chart

1 Month Hemogenyx Chart

Intraday Hemogenyx Chart

Intraday Hemogenyx Chart

Hemogenyx (HEMO) Discussions and Chat

Hemogenyx Forums and Chat

Date Time Title Posts
19/9/201817:33HEMOGENYX 2018/19 Moderated536
10/8/201810:16HEMO824
08/8/201818:39Hemogenyx Pharmaceuticals Plc MODERATED134

Add a New Thread

Hemogenyx (HEMO) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
15:36:353.00100,0003,000.00O
15:33:402.9050,0001,450.00O
14:58:463.0040,0001,200.00O
14:56:182.833,50099.05O
14:51:532.8346,7881,324.10O
View all Hemogenyx trades in real-time

Hemogenyx (HEMO) Top Chat Posts

DateSubject
19/9/2018
09:20
Hemogenyx Daily Update: Hemogenyx is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HEMO. The last closing price for Hemogenyx was 2.60p.
Hemogenyx has a 4 week average price of 2.43p and a 12 week average price of 2.43p.
The 1 year high share price is 6.75p while the 1 year low share price is currently 2.05p.
There are currently 356,042,854 shares in issue and the average daily traded volume is 191,314 shares. The market capitalisation of Hemogenyx is £10,681,285.62.
03/9/2018
20:33
tullynessle: Re Post 494 https://uk.advfn.com/stock-market/london/hemogenyx-HEMO/share-news/Hemogenyx-Pharmaceuticals-PLC-Hemogenyx-to-present/78177372 Hemogenyx Pharmaceuticals PLC Hemogenyx to present at Oxford conference 03/09/2018 7:00am UK Regulatory (RNS & others) Hemogenyx to Present at the 'From Laboratory to Clinic' Translational Research Conference in Oxford Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the Standard Listed biopharmaceutical group developing new therapies and treatments designed to transform bone marrow transplantation for the treatment of blood diseases, announces that its CEO, Dr. Vladislav Sandler, will present at the Kennedy Institute of Rheumatology conference 'From Laboratory to Clinic: Accelerating Experimental Medicine Approaches' taking place at Trinity College, Oxford, from Tuesday 4 September until Friday 7 September 2018. Continued.....
01/8/2018
16:20
badger60: The PR effort from this company is abysmal! Considering the very upbeat presentation was not even 2 months ago, the response has been appalling! I believe that the potential here is phenomenal......but PERLEEERSE!! the management MUST do something proactive to promote the company and its products to the investment community.......even a modest fee paying contract for Hemogenyx's chimaeric mice, with a mkt cap of less than £10 Mio, could easily X3 the share price.....and more importantly put this company above the radar.....
27/6/2018
12:08
badger60: My friend, a significant HEMO shareholder, attended yesterday and sent me this last night.....My question on monetizing mice went down well the answer is that $375k already this year and $3 m in three years and $4m in five years. This will reduce cash burn to zero . Car-t and hemogenyx are totally separate for different cancers and one cannot be used to treat the same cancer as Hemo are targeting as the delivery systems are totally different. Hemo uses antibodies which are 100 smaller and more deliverable than a t cell. Sanofi Roche and Pfizer are the only companies that fit the market cap that is eluded to as being big enough for the tie up to get Hemogenyx list of antibodies to get FDA approval. The company will collaborate with Hemogenyx and pay the cost of obtaining approval so negating the need for massive rights issue. Hemogenyx royalties will be a lot less but say 10%. An example is AML which is expected to cost .5m dollars per course and 10m expected cases in the states gives $5m a patient may need multiple courses say only 2 that's 10m in the states and roughly same for europe so one antibody upwards of $20m and say they get 10% that's $2bn per antibody to Hemogenyx year after year. It's not difficult to see that in five years time the income could be the same as the current market cap. Then times that by the large number of antibodies and the sky's the limit! A cautionary note Hemogenyx was reversed into a fintech company and coo reckons half free float of 100m shares are in weak hands and are sellers at 5-6p so they get out flat from the original company once they are gone in estimated 1 year then they believe share price will be 9-10 p. All of this is subject to filing at the fda and i think it will be around 12p on that news!! I have a presentation pack which i can photo and send but it is no extra news than you already know.
04/6/2018
14:35
badger60: It's all relative. Hemogenyx is a small and nimble £13mio mkt cap biotech with low overhead, which has laid the groundwork for potentially huge gains during the course of the run up to its products development. As such, a relatively modest income stream seperate from the core treatment products, eg. revenue from 3rd party licenced use of their humanised mice, would have a beneficial impact on the share price. It would also go a long way to help provide the financing out to phase 3 product development, without diluting shareholders. Much of this was spoken about by Dr. Sandler in a recent YouTube video.
21/5/2018
12:38
mam fach: Buying now is close to the bottom . Not on investors radar yet. IF they are successful (IT is a mighty big IF) We are talking many multiples of today's share price.
14/5/2018
09:50
badger60: I disagree entirely!!!! The fact that there is a "global pharma" substantively interested in progressing and developing Hemogenyx's IP free of charge adds huge value to the company and should/will be reflected in the share price......
22/3/2018
10:33
pwhite73: krowlete I agree about the no bad news at all. Following on from that you may wish to explain how the share price collapsed to 2p so shortly after the 3.5p listing. I think forward selling started from the very day they listed.
21/3/2018
18:23
pwhite73: OT The nominal value is 1p but when or if shares are issued the company can issue shares at a price of 1p or £10.00 if the share price is high enough. When looking at the possible issuance of new shares you need to look at the current share price and the nominal value. The current share price is 2.45p. What that means is if they were to issue shares at a discount the new shares will not be too far from 1p the nominal value. If the shares were currently trading at £10.00 then the nominal value of 1p and the new shares being priced at 1p would not be a matter of concern for anybody. I hope I've made it clear why I'm rabbiting on about a share issue at 1p the same as the nominal price of 1p.
20/3/2018
10:53
pwhite73: On Target But you need to look at how close the nominal value is to current share price. Gone.
20/3/2018
10:48
pwhite73: That is correct but given placings are normally at a discount you need to be mindful of the current share price and at what level they can place new shares at. You need to look at the price before the spike because that's where it's heading.
Hemogenyx share price data is direct from the London Stock Exchange
add chat code
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20180919 17:25:20